Gyre Therapeutics Files 8-K on Operations and Financials
Ticker: GYRE · Form: 8-K · Filed: May 9, 2024 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | May 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, filing
TL;DR
Gyre Therapeutics dropped an 8-K detailing its financials and operations. Check it out.
AI Summary
Gyre Therapeutics, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Catalyst Biosciences, Inc. and Targacept Inc.
Why It Matters
This filing provides an update on Gyre Therapeutics' financial health and operational status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing reporting on financial condition and operations, not indicating any immediate or significant new risks.
Key Players & Entities
- Gyre Therapeutics, Inc. (company) — Registrant
- May 9, 2024 (date) — Date of report
- Catalyst Biosciences, Inc. (company) — Former company name
- Targacept Inc (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- 12770 High Bluff Drive Suite 150 San Diego , CA 92130 (address) — Principal executive offices
- ( 858 ) 567-7770 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Gyre Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Gyre Therapeutics, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 9, 2024.
What were Gyre Therapeutics, Inc.'s former names?
Gyre Therapeutics, Inc. was formerly known as Catalyst Biosciences, Inc. and Targacept Inc.
Where are Gyre Therapeutics, Inc.'s principal executive offices located?
Gyre Therapeutics, Inc.'s principal executive offices are located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
What is the telephone number for Gyre Therapeutics, Inc.?
The telephone number for Gyre Therapeutics, Inc. is (858) 567-7770.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-05-09 16:05:45
Filing Documents
- gyre-20240509.htm (8-K) — 44KB
- gyre-ex99_1.htm (EX-99.1) — 250KB
- img51893664_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-056893.txt ( ) — 438KB
- gyre-20240509.xsd (EX-101.SCH) — 25KB
- gyre-20240509_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 9, 2024, Gyre Therapeutics, Inc. issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated herein shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated May 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: May 9, 2024 By: /s/ Han Ying, Ph.D. Name: Han Ying, Ph.D. Title: Chief Executive Officer